Category - Developments

Developments

Karyopharm Therapeutics doses first glioblastoma patient in Phase 1/2 selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 1/2 clinical study evaluating oral selinexor in patients with newly diagnosed or recurrent glioblastoma (GBM). This global study is expected to...

June 9, 2020

Developments

MD Anderson resumes Phase 1b trial of Soricimed’s SOR-C13

Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center has resumed its investigator-initiated trial of Soricimed’s SOR-C13. MD Anderson completed the first cohort of the dose escalation phase of...

June 9, 2020

Developments

IntelGenx receives Health Canada cannabis micro-processing license

IntelGenx (TSXV:IGX; OTCQB:IGXT) received a cannabis micro-processing license from Health Canada under the Cannabis Act and Cannabis Regulations for the company’s Montreal, Quebec facility. “Receipt of this cannabis...

June 8, 2020

Developments

MacroGenics margetuximab gets FDA orphan drug designation for gastric cancer

MacroGenics’ (NASDAQ:MGNX) margetuximab received FDA orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in a Phase 2/3 trial in...

June 5, 2020

Developments

Tenax posts positive Phase 2 levosimendan data

Tenax Therapeutics (NASDAQ:TENX) reported positive results from a Phase 2 trial evaluating levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH...

June 4, 2020

Developments

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Idera Pharma (NASDAQ:IDRA) reported positive preliminary data from its Phase 2 trial of tilsotolimod, in combination with Opdivo and Yervoy, in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC)...

June 4, 2020

Developments

Menlo Therapeutics reports positive data from Phase 2 acne vulgaris trial

Menlo Therapeutics (NASDAQ:MNLO) reported positive results from its Phase 2 trial evaluating FCD105 or the treatment of moderate-to-severe acne vulgaris. The study enrolled 447 patients who received either FCD105, a 3%...

June 4, 2020

Developments

PharmAust lab tests show positive signs for suppressing COVID-19

PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...

June 4, 2020

Developments

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...

June 1, 2020

Developments

Menlo Therapeutics ZILXI gets FDA approval for rosacea

Menlo Therapeutics’ (NASDAQ:MNLO) ZILXI received FDA approval for the treatment of inflammatory lesions of rosacea in adults. The company noted that ZILXI, a minocycline topical foam, is the first minocycline product of...

May 29, 2020

Category - Developments

Karyopharm Therapeutics doses first glioblastoma patient in Phase 1/2 selinexor study

MD Anderson resumes Phase 1b trial of Soricimed’s SOR-C13

IntelGenx receives Health Canada cannabis micro-processing license

MacroGenics margetuximab gets FDA orphan drug designation for gastric cancer

Tenax posts positive Phase 2 levosimendan data

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Menlo Therapeutics reports positive data from Phase 2 acne vulgaris trial

PharmAust lab tests show positive signs for suppressing COVID-19

Ocugen to discontinue Phase 3 oGVHD trial

Menlo Therapeutics ZILXI gets FDA approval for rosacea

General

More